Barrett oesophagus is thought to have a prevalence of 3-15% in patients with reflux oesophagitis. Mean age at diagnosis is 55 years old 5. Risk factors are similar to those for gastro-oesophageal reflux disease (GORD).
Scleroderma is thought to be a risk factor, with ~37% of patients (n = 27) who underwent upper endoscopy were found to have Barrett oesophagus 5.
Asymptomatic. Usually discovered in a workup for GORD.
Barrett oesophagus represents progressive metaplasia of oesophageal stratified squamous cell epithelium to columnar epithelium. Although the exact number varies, 90-100% of oesophageal adenocarcinoma is thought to arise from this metaplasia.
Although patients with Barrett oesophagus have a 30x risk of developing oesophageal adenocarcinoma 2, the annual risk of developing adenocarcinoma depends on the degree of histological dysplasia, but may be ~1% (range 0.1-2%), and the absolute risk is low 3.
Because Barrett oesophagus represents metaplasia, it is often occult on imaging. Early oesophageal adenocarcinoma arising out of Barrett oesophagus also may be difficult to see. Radiographic imaging modalities are not adequate for screening.
double-contrast oesophagogram 7
- signs of reflux oesophagitis
- long stricture in the mid or lower oesophagus
- large deep solitary ulcer
- fine reticular mucosal pattern
- thickened irregular mucosal folds
- earliest signs of developing adenocarcinoma: localised flattening, stiffening, or irregularity in the wall of a stricture
- signs of reflux oesophagitis
There is a ~70% chance of Barrett oesophagus in a midthoracic oesophageal stricture.
Treatment and prognosis
Since Barrett oesophagus is considered a premalignant lesion, confirmation with upper endoscopy and biopsy is warranted.
If Barrett oesophagus is confirmed on biopsy, then aggressive therapy for gastro-oesophageal reflux is pursued, and perhaps endoscopic surveillance, depending on the patient's age and other risk factors.
One surveillance and biopsy protocol suggests 4:
- low-grade dysplasia: 6-12 months
- high-grade dysplasia: 3 months
If there is mucosal irregularity (what would be seen on an esophagogram), then endoscopic resection has been recommended 4. Prophylactic resection or ablation has been used by some, particularly in younger patients.
- 1. Spechler SJ. Clinical practice. Barrett's Esophagus. N. Engl. J. Med. 2002;346 (11): 836-42. doi:10.1056/NEJMcp012118 - Pubmed citation
- 2. Rastogi A, Puli S, El-Serag HB et-al. Incidence of esophageal adenocarcinoma in patients with Barrett's esophagus and high-grade dysplasia: a meta-analysis. Gastrointest. Endosc. 2008;67 (3): 394-8. doi:10.1016/j.gie.2007.07.019 - Pubmed citation
- 3. Van der Veen AH, Dees J, Blankensteijn JD et-al. Adenocarcinoma in Barrett's oesophagus: an overrated risk. Gut. 1989;30 (1): 14-8. Free text at pubmed - Pubmed citation
- 4. , Spechler SJ, Sharma P et-al. American Gastroenterological Association medical position statement on the management of Barrett's esophagus. Gastroenterology. 2011;140 (3): 1084-91. doi:10.1053/j.gastro.2011.01.030 - Pubmed citation
- 5. Spechler SJ. Barrett's esophagus. Semin. Gastrointest. Dis. 1996;7 (2): 51-60. Pubmed citation
- 6. Recht MP, Levine MS, Katzka DA et-al. Barrett's esophagus in scleroderma: increased prevalence and radiographic findings. Gastrointest Radiol. 1988;13 (1): 1-5. doi:10.1007/BF01889012 - Pubmed citation
- 7. Gilchrist AM, Levine MS, Carr RF et-al. Barrett's esophagus: diagnosis by double-contrast esophagography. AJR Am J Roentgenol. 1988;150 (1): 97-102. doi:10.2214/ajr.150.1.97 - Pubmed citation
- oesophageal dysmotility
- oesophageal tumours
- benign oesophageal neoplasms
- malignant oesophageal neoplasms
- gastro-oesophageal reflux disease
- oesophageal stricture